156 related articles for article (PubMed ID: 38630912)
1. Preclinical models for bladder cancer therapy research.
Ertl I; Shariat SF; Berger W; Englinger B
Curr Opin Urol; 2024 Jul; 34(4):244-250. PubMed ID: 38630912
[TBL] [Abstract][Full Text] [Related]
2. Fidelity of a PDX-CR model for bladder cancer.
Mondal AM; Ma AH; Li G; Krawczyk E; Yuan R; Lu J; Schlegel R; Stamatakis L; Kowalczyk KJ; Philips GK; Pan CX; Liu X
Biochem Biophys Res Commun; 2019 Sep; 517(1):49-56. PubMed ID: 31303270
[TBL] [Abstract][Full Text] [Related]
3. Patient-derived xenografts as in vivo models for research in urological malignancies.
Inoue T; Terada N; Kobayashi T; Ogawa O
Nat Rev Urol; 2017 May; 14(5):267-283. PubMed ID: 28248952
[TBL] [Abstract][Full Text] [Related]
4. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine.
Pamarthy S; Sabaawy HE
Mol Cancer; 2021 Sep; 20(1):125. PubMed ID: 34587953
[TBL] [Abstract][Full Text] [Related]
5. Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer.
Lee SH; Hu W; Matulay JT; Silva MV; Owczarek TB; Kim K; Chua CW; Barlow LJ; Kandoth C; Williams AB; Bergren SK; Pietzak EJ; Anderson CB; Benson MC; Coleman JA; Taylor BS; Abate-Shen C; McKiernan JM; Al-Ahmadie H; Solit DB; Shen MM
Cell; 2018 Apr; 173(2):515-528.e17. PubMed ID: 29625057
[TBL] [Abstract][Full Text] [Related]
6. Patient-Derived Xenograft Models for Translational Prostate Cancer Research and Drug Development.
Philp LK
Methods Mol Biol; 2024; 2806():153-185. PubMed ID: 38676802
[TBL] [Abstract][Full Text] [Related]
7. Patient-Derived Xenografts: A Valuable Preclinical Model for Drug Development and Biomarker Discovery.
Weng T; Jenkins BJ; Saad MI
Methods Mol Biol; 2024; 2806():19-30. PubMed ID: 38676793
[TBL] [Abstract][Full Text] [Related]
8. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.
Vlachogiannis G; Hedayat S; Vatsiou A; Jamin Y; Fernández-Mateos J; Khan K; Lampis A; Eason K; Huntingford I; Burke R; Rata M; Koh DM; Tunariu N; Collins D; Hulkki-Wilson S; Ragulan C; Spiteri I; Moorcraft SY; Chau I; Rao S; Watkins D; Fotiadis N; Bali M; Darvish-Damavandi M; Lote H; Eltahir Z; Smyth EC; Begum R; Clarke PA; Hahne JC; Dowsett M; de Bono J; Workman P; Sadanandam A; Fassan M; Sansom OJ; Eccles S; Starling N; Braconi C; Sottoriva A; Robinson SP; Cunningham D; Valeri N
Science; 2018 Feb; 359(6378):920-926. PubMed ID: 29472484
[TBL] [Abstract][Full Text] [Related]
9. Establishment of a novel experimental model for muscle-invasive bladder cancer using a dog bladder cancer organoid culture.
Elbadawy M; Usui T; Mori T; Tsunedomi R; Hazama S; Nabeta R; Uchide T; Fukushima R; Yoshida T; Shibutani M; Tanaka T; Masuda S; Okada R; Ichikawa R; Omatsu T; Mizutani T; Katayama Y; Noguchi S; Iwai S; Nakagawa T; Shinohara Y; Kaneda M; Yamawaki H; Sasaki K
Cancer Sci; 2019 Sep; 110(9):2806-2821. PubMed ID: 31254429
[TBL] [Abstract][Full Text] [Related]
10. Bladder Cancer Patient-derived Organoids and Avatars for Personalized Cancer Discovery.
Kim YS; Hsieh AC; Lam HM
Eur Urol Focus; 2022 May; 8(3):657-659. PubMed ID: 35915037
[TBL] [Abstract][Full Text] [Related]
11. Establishment of experimental salivary gland cancer models using organoid culture and patient-derived xenografting.
Aizawa Y; Takada K; Aoyama J; Sano D; Yamanaka S; Seki M; Kuze Y; Ramilowski JA; Okuda R; Ueno Y; Nojima Y; Inayama Y; Hatakeyama H; Hatano T; Takahashi H; Nishimura G; Fujii S; Suzuki Y; Taniguchi H; Oridate N
Cell Oncol (Dordr); 2023 Apr; 46(2):409-421. PubMed ID: 36538240
[TBL] [Abstract][Full Text] [Related]
12. Patient-Derived Bladder Cancer Xenografts.
Bernardo C; Santos LL
Methods Mol Biol; 2018; 1655():169-175. PubMed ID: 28889386
[TBL] [Abstract][Full Text] [Related]
13. Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients.
Wu H; Wang W; Zhang Y; Chen Y; Shan C; Li J; Jia Y; Li C; Du C; Cai Y; Zhang Y; Zhang S; Wu F
Int J Cancer; 2024 Jul; 155(2):324-338. PubMed ID: 38533706
[TBL] [Abstract][Full Text] [Related]
14. Preclinical models as patients' avatars for precision medicine in colorectal cancer: past and future challenges.
Durinikova E; Buzo K; Arena S
J Exp Clin Cancer Res; 2021 Jun; 40(1):185. PubMed ID: 34090508
[TBL] [Abstract][Full Text] [Related]
15. Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies.
Jäger W; Xue H; Hayashi T; Janssen C; Awrey S; Wyatt AW; Anderson S; Moskalev I; Haegert A; Alshalalfa M; Erho N; Davicioni E; Fazli L; Li E; Collins C; Wang Y; Black PC
Oncotarget; 2015 Aug; 6(25):21522-32. PubMed ID: 26041878
[TBL] [Abstract][Full Text] [Related]
16. Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation.
Kang HN; Choi JW; Shim HS; Kim J; Kim DJ; Lee CY; Hong MH; Park SY; Park AY; Shin EJ; Lee SY; Pyo KH; Yun MR; Choi HM; Lee SS; Kim SY; Lee H; Paik S; Cho BC; Lee JG; Kim HR
Lung Cancer; 2018 Oct; 124():168-178. PubMed ID: 30268457
[TBL] [Abstract][Full Text] [Related]
17. Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy.
Lee HW; Lee JI; Lee SJ; Cho HJ; Song HJ; Jeong DE; Seo YJ; Shin S; Joung JG; Kwon YJ; Choi YL; Park WY; Lee HM; Seol HJ; Shim YM; Joo KM; Nam DH
Clin Cancer Res; 2015 Mar; 21(5):1172-82. PubMed ID: 25549722
[TBL] [Abstract][Full Text] [Related]
18. Conditional Reprogramming Modeling of Bladder Cancer for Clinical Translation.
Daneshdoust D; Yin M; Luo M; Sundi D; Dang Y; Lee C; Li J; Liu X
Cells; 2023 Jun; 12(13):. PubMed ID: 37443748
[TBL] [Abstract][Full Text] [Related]
19. Modeling rectal cancer to advance neoadjuvant precision therapy.
Janakiraman H; Zhu Y; Becker SA; Wang C; Cross A; Curl E; Lewin D; Hoffman BJ; Warren GW; Hill EG; Timmers C; Findlay VJ; Camp ER
Int J Cancer; 2020 Sep; 147(5):1405-1418. PubMed ID: 31989583
[TBL] [Abstract][Full Text] [Related]
20. Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug Responses.
de Witte CJ; Espejo Valle-Inclan J; Hami N; Lõhmussaar K; Kopper O; Vreuls CPH; Jonges GN; van Diest P; Nguyen L; Clevers H; Kloosterman WP; Cuppen E; Snippert HJG; Zweemer RP; Witteveen PO; Stelloo E
Cell Rep; 2020 Jun; 31(11):107762. PubMed ID: 32553164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
